Versant Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$47.5K Sell
1,021
-5
-0.5% -$240 ﹤0.01% 1395
2026
Q1
$53K Buy
1,026
+33
+3% +$1.68K 0.01% 1203
2025
Q4
$49.4K Hold
993
0.01% 1106
2025
Q3
$47.5K Sell
993
-6
-0.6% -$242 0.01% 1069
2025
Q2
$31.5K Sell
999
-126
-11% -$4.04K ﹤0.01% 1247
2025
Q1
$36.8K Buy
1,125
+1,109
+6,931% +$39.3K 0.01% 1001
2024
Q4
$579 Hold
16
﹤0.01% 2260
2024
Q3
$499 Hold
16
﹤0.01% 1867
2024
Q2
$428 Hold
16
﹤0.01% 1815
2024
Q1
$546 Hold
16
﹤0.01% 1675
2023
Q4
$463 Buy
+16
New +$424 ﹤0.01% 1701
2023
Q3
Sell
-19
Closed -$571 2052
2023
Q2
$571 Buy
+19
New +$665 ﹤0.01% 1802
2021
Q2
Sell
-559
Closed -$15K 1586
2021
Q1
$15K Sell
559
-185
-25% -$5.17K 0.01% 655
2020
Q4
$18K Sell
744
-24
-3% -$517 0.01% 547
2020
Q3
$16K Hold
768
0.01% 506
2020
Q2
$18K Buy
768
+192
+33% +$4.24K 0.01% 459
2020
Q1
$10K Buy
+576
New +$12.1K 0.01% 562
2019
Q4
Sell
-26
Closed 1562
2019
Q3
$0 Buy
+26
New +$770 ﹤0.01% 1573

Other funds holding SUPN

Versant Capital Management's SUPN Position: Q2 2026 in Review

Versant Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 0.49% in Q2 2026, selling an estimated $240 and leaving 1,021 shares worth $47.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1395.

Versant Capital Management first reported a position in SUPN in Q3 2019 and has held it in 18 quarters since. The position peaked at $53K in Q1 2026. 50 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Versant Capital Management held 1,021 shares of Supernus Pharmaceuticals worth $47.5K as of Q2 2026.
  • Versant Capital Management sold 5 Supernus Pharmaceuticals shares in Q2 2026, an estimated $240.
  • Supernus Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1395 holding.
  • Versant Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2019 and has held it in 18 quarters since.
  • Versant Capital Management's Supernus Pharmaceuticals position peaked at $53K in Q1 2026.
  • 50 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.